# Antibacterial and Antibiofilm Effects of L-Carnitine-Fumarate on Oral Streptococcal Strains Streptococcus mutans and Streptococcus sobrinus

**Authors:** Anna Goc, Waldemar Sumera, Matthias Rath, Aleksandra Niedzwiecki

PMC · DOI: 10.3390/microorganisms12081613 · Microorganisms · 2024-08-07

## TL;DR

This study explores L-carnitine-fumarate's ability to fight oral bacteria and biofilms linked to tooth decay.

## Contribution

The paper introduces L-carnitine-fumarate as a novel antibiofilm and antibacterial agent against Streptococcus mutans and Streptococcus sobrinus.

## Key findings

- L-carnitine-fumarate inhibits biofilm formation and reduces pre-existing biofilm by 20% at 10.0 mg/mL.
- It effectively suppresses extracellular polymeric substance (EPS) formation at 10.0 mg/mL.
- Sub-MIC concentrations show anti-adherent and anti-aciduric effects on the bacteria.

## Abstract

Streptococcus mutans is a major pathogenic habitant of oral caries. Owing to its physiological and biochemical features, it prevails in the form of plaque biofilm together with another important mutans streptococci species, Streptococcus sobrinus. Both species are considered as initiators of cavity lesions, and biofilm is essential to the dental caries process. Compared with the planktonic populations, the biofilm form has higher resistance to environmental conditions and antibiotics. Dental plaques also secure the long-term survival of microorganisms and protection from any stress conditions. To address the need for new antibiofilm agents, we have focused on L-carnitine-fumarate, a fumarate-conjugated quaternary ammonium compound. Using the macro-broth susceptibility testing method, we established its MIC value as 6.0 mg/mL. The MBC value, determined from the broth dilution minimum inhibitory concentration test by sub-culturing it to BHI agar plates, was established as 7.0 mg/mL. Antibiofilm efficacy was tested in 96-well plates coated with saliva using BHI broth supplemented with 1% sucrose as a standard approach. The obtained results allowed us to assess the MIBC as 7.5 mg/mL and the MBBC value as 10.0 mg/mL. The latter concentration also caused approximately 20% eradication of pre-existing biofilm. EPS-rich matrix, forming the core of the biofilm and enabling a confined acidic microenvironment, was also examined and confirmed the effectiveness of 10.0 mg/mL L-carnitine-fumarate concentration in inhibiting EPS formation. Furthermore, the anti-adherent and anti-aciduric impacts of L-carnitine-fumarate were investigated and revealed significant inhibitory effects at sub-MIC concentrations. The influence of L-carnitine-fumarate on the phosphotransferase system was investigated as well. Our results provide a new insight into the antibacterial potential of L-carnitine-fumarate as a valuable compound to be considered for alternative or adjunct anti-caries and antibiofilm preventive approaches.

## Linked entities

- **Chemicals:** L-carnitine-fumarate (PubChem CID 109374093)
- **Species:** Streptococcus mutans (taxon 1309), Streptococcus sobrinus (taxon 1310)

## Full-text entities

- **Diseases:** caries (MESH:D003731)
- **Chemicals:** BHI agar (-), sucrose (MESH:D013395), fumarate (MESH:D005650), EPS (MESH:C100219)
- **Species:** Streptococcus sobrinus (species) [taxon 1310], Streptococcus mutans (species) [taxon 1309]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11356751/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11356751/full.md

## References

50 references — full list in the complete paper: https://tomesphere.com/paper/PMC11356751/full.md

---
Source: https://tomesphere.com/paper/PMC11356751